Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice DOI
Sabrina Mendes, Lays Cordeiro Guimarães, Pedro Augusto Carvalho Costa

et al.

Antimicrobial Agents and Chemotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 29, 2024

ABSTRACT To effectively reduce the health impact of coronavirus disease (COVID-19), it is essential to adopt comprehensive strategies protect individuals from severe acute respiratory syndrome. In that sense, much effort has been devoted discovery and repurposing effective antiviral anti-inflammatory molecules. The endogenous peptide angiotensin-(1-7) [Ang-(1-7)] recently proposed as a promising agent control infections. Liposomes also emerged safe drug carrier system for local delivery lungs. this context, aim study was develop liposomal formulation Ang-(1-7) [LAng (1-7)] investigate its on animal survival well efficacies after intranasal administration in transgenic K18-hACE2 mice infected with SARS-CoV-2. prepared by ethanol injection method, exhibiting mean diameter 100 nm polydispersity index 0.1. Following treatment every 12 hours 5 days, LAng (1-7) extended compared groups received either empty liposomes, free Ang-(1-7), or phosphate-buffered saline. Furthermore, significantly decreased viral load, IL-6 tumor necrosis factor levels Conventional remdesivir parenteral route used positive promoted similar effects, leading improved rates reduced load lungs without significant effects level. conclusion, emerges improve decrease severity infections, such COVID-19.

Language: Английский

Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice DOI

Vinícius Amorim Beltrami,

Flávia Rayssa Braga Martins,

Débora Gonzaga Martins

et al.

Inflammation Research, Journal Year: 2025, Volume and Issue: 74(1)

Published: Jan. 25, 2025

Language: Английский

Citations

1
Intranasal liposomal angiotensin-(1-7) administration reduces inflammation and viral load in the lungs during SARS-CoV-2 infection in K18-hACE2 transgenic mice DOI
Sabrina Mendes, Lays Cordeiro Guimarães, Pedro Augusto Carvalho Costa

et al.

Antimicrobial Agents and Chemotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 29, 2024

ABSTRACT To effectively reduce the health impact of coronavirus disease (COVID-19), it is essential to adopt comprehensive strategies protect individuals from severe acute respiratory syndrome. In that sense, much effort has been devoted discovery and repurposing effective antiviral anti-inflammatory molecules. The endogenous peptide angiotensin-(1-7) [Ang-(1-7)] recently proposed as a promising agent control infections. Liposomes also emerged safe drug carrier system for local delivery lungs. this context, aim study was develop liposomal formulation Ang-(1-7) [LAng (1-7)] investigate its on animal survival well efficacies after intranasal administration in transgenic K18-hACE2 mice infected with SARS-CoV-2. prepared by ethanol injection method, exhibiting mean diameter 100 nm polydispersity index 0.1. Following treatment every 12 hours 5 days, LAng (1-7) extended compared groups received either empty liposomes, free Ang-(1-7), or phosphate-buffered saline. Furthermore, significantly decreased viral load, IL-6 tumor necrosis factor levels Conventional remdesivir parenteral route used positive promoted similar effects, leading improved rates reduced load lungs without significant effects level. conclusion, emerges improve decrease severity infections, such COVID-19.

Language: Английский

Citations

1